Eight Roads

Eight Roads Ventures is a global venture capital firm and the proprietary investment arm of Fidelity International Limited, with offices in China, India, Japan, and the UK. The firm focuses on early venture and growth stage investments, primarily in technology sectors such as software as a service, healthcare IT, financial technology, and telecommunications. It seeks to invest in emerging growth companies across Asia, Europe, and Israel, typically committing between $1.29 million and $30 million. Eight Roads Ventures aims to take minority or majority stakes in its portfolio companies and prefers to hold board seats. The firm has various specialized funds, including those targeting healthcare and technology in China, further solidifying its commitment to fostering innovation in dynamic markets.

Umang Agarwal

Principal

Sanjay Aggarwal

Venture Partner

Hiroki Ashida

Vice President

Daniel Auerbach

Senior Managing Partner, Asia

Vytautas Balsys

Partner

Helena Barman

Investor

Katy Barnett

Associate

Helen Barton

Finance Director

Virginia Bassano

Senior Associate

Shirish Belapure

Venture Partner

Daniel Benjamin

Associate

Shweta Bhatia

Partner and Head of Technology Investments, India

Harvinderjit Bhatia

Venture Partner

Bhushan Bopardikar

Vice President

Betty Cai

Principal and Partner

Ted Chua

Senior Partner

Dekkers Davidson

Venture Partner

Kevin Du

Senior Associate

Raj Dugar

Managing Partner, India

Martin Ericsson

Principal

Tamina Fogelberg

Associate

Siddhant Gandhi

Associate

Elaine Gao

Senior Associate

Antonin Gury-Coupier

Vice President

Davor Hebel

Partner, Head of Europe Ventures

April Hu

Vice President

Tammy Huang

Senior Associate

Tao Huang

Principal

Allen Huo

Vice President

Abhishek Jain

Vice President

Zang Jialun

Partner

Deepak Kanvinde

Venture Partner

Michiko Kohyama

Vice President

Shinichiro Komoto

Partner

Kavish Kothari

Vice President

Chintan Kothari

Partner

Thomas Lin

Vice President

Xin Liu

Partner

Allen Liu

Senior Associate

Maneesh Menon

Principal

Sophie Meralli

Vice President

Chersy Miao

Senior Associate

David Milstein

Managing Partner, Head of Japan

Jens Neisius

Vice President

Dan O'Toole

Vice President

Yosuke Ouchi

Principal

Prem Pavoor

Partner and Head of India

Alexandra Prescot

Investor

Delphine Qiu

Principal

Pallavi Rathi

Senior Associate

Laura Salesse

Senior Associate

Fuga Sawada

Senior Associate

Shawn Shen

Partner

Sagar Sheth

Vice President

Lei Shi

Partner

Prakhar Singh

Vice President

Arjun Singh

Senior Associate

Michael Stephanblome

Venture Partner

Liena Suzuki

Principal

Aditya Gurunath Systla

Partner

Michael Treskow

Partner

Jarlon Tsang

Managing Partner, Head of China

Ashish Venkataramani

Partner

He Wang

Vice President

Bo Wang

Senior Associate

Nancy Xu

Vice President

Cody Yin

Partner

Yuan Yuan

Principal

Cai Yuanxun

Partner

Alston Zecha

FinTech and Enterprise Software and Director

Haoming Zhang

Vice President

Gordon Zhang

Partner

Feng Zhao

Partner

Weimin Liu Ph.D

Partner

Past deals in New Jersey

Spry

Series A in 2022
Spry is a cloud-based operating system that allows movement health professionals to collect and analyze patient data in real time.

Doceree

Series A in 2022
Doceree is a healthcare marketing technology company. They specialize in providing a platform and solutions for pharmaceutical and healthcare brands to connect with healthcare professionals (HCPs). Doceree's platform may include features like targeted advertising, data analytics, and tools to help pharmaceutical companies and healthcare brands effectively reach and engage with healthcare professionals in a compliant and efficient manner.

B-One

Venture Round in 2020
b-ONE Ortho Corp. develops orthopedic healthcare solutions. The company’s product includes B-One total hip system which features coating technology and instrumentation. The system includes the Juveno bone-conserving femoral prosthesis and the B-One primary acetabular systems. b-ONE Ortho Corp. was founded in 2015 and is based in Cedar Knolls, New Jersey. The company has additional offices in Shanghai and Suzhou, China.

B-One

Series A in 2018
b-ONE Ortho Corp. develops orthopedic healthcare solutions. The company’s product includes B-One total hip system which features coating technology and instrumentation. The system includes the Juveno bone-conserving femoral prosthesis and the B-One primary acetabular systems. b-ONE Ortho Corp. was founded in 2015 and is based in Cedar Knolls, New Jersey. The company has additional offices in Shanghai and Suzhou, China.

B-One

Venture Round in 2018
b-ONE Ortho Corp. develops orthopedic healthcare solutions. The company’s product includes B-One total hip system which features coating technology and instrumentation. The system includes the Juveno bone-conserving femoral prosthesis and the B-One primary acetabular systems. b-ONE Ortho Corp. was founded in 2015 and is based in Cedar Knolls, New Jersey. The company has additional offices in Shanghai and Suzhou, China.

Symbiomix Therapeutics

Venture Round in 2018
Symbiomix Therapeutics, LLC is a biopharmaceutical company focused on developing innovative treatments for serious women's health infections, particularly bacterial vaginosis (BV). Founded in 2012, the company is based in Newark, New Jersey, with additional offices in Baltimore, Maryland, and Hamden, Connecticut. Its lead product, Solosec (secnidazole), is a novel 5-nitroimidazole antibiotic designed for a one-time oral treatment of bacterial vaginosis, addressing a significant unmet need in women's healthcare. Symbiomix operates as a subsidiary of Lupin Inc. and is supported by prominent healthcare venture capital firms. The company aims to provide effective therapeutic options for gynecologic infections that have been historically overlooked.

Transave

Venture Round in 2006
Transave, Inc., a biotechnology company, develops inhaled pharmaceuticals for the treatment of lung diseases. The company’s liposomal technology allows the release of drug in the lung's microenvironment. Its products also include Arikace for the treatment of gram-negative lung infections and pseudomonas infections in cystic fibrosis patients; and cisplatin lipid complex for the treatment of cancers affecting the lungs. Transave, Inc. was founded in 1997 and is headquartered in Monmouth Junction, New Jersey. As of December 1, 2010, Transave, Inc. operates as a subsidiary of Insmed Incorporated.

QUMAS

Venture Round in 2005
QUMAS specializes in enterprise compliance management software, offering an integrated platform that standardizes and streamlines compliance tasks for organizations across various industries. The company focuses on delivering a closed-loop compliance model that allows enterprises to consolidate their compliance programs, significantly reducing costs and enhancing competitive advantage. With a strong track record in highly regulated sectors such as financial services and life sciences, QUMAS is well-equipped to support centralized compliance efforts for any organization. Its solutions help ensure adherence to a comprehensive range of global regulations, making it a valuable partner for businesses navigating complex compliance landscapes.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.